The US market is currently closed. It will re-open at from 13:30, 13 April.
This company is developing new treatments targeting G-protein-coupled receptors. Its main drug, TX45, is being tested in early clinical trials for a severe heart condition called Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). It has another project focussed on Hereditary Hemorrhagic Telangiectasia (HHT), a common genetic bleeding disorder. This company consolidated with AVROBIO Inc in June 2024.
Health
Sector
Freetrade is your gateway to commission-free investing. Join over 1.6 million users using the Best online trading platform, as voted at the British Bank Awards for six years running.
Freetrade does not provide investment advice and individual investors should make their own decisions or seek independent advice. The value of investments can go down as well as up and you may receive back less than your original investment. Past performance is not a reliable indicator of future returns. Freetrade is a trading name of Freetrade Limited, which is a member firm of the London Stock Exchange and is authorised and regulated by the Financial Conduct Authority. Registered in England and Wales (no. 09797821).
© 2026 Freetrade, All rights reserved. The Apple logo is a trademark of Apple Inc. App Store is a service mark of Apple Inc. Google Play and the Google Play logo are trademarks of Google LLC.
